We Compiled the Most Important Facts About Roivant Sciences

By Blake Campbell • Friday, January 06 12:00 • Permanent Link

Shares of Biotechnology company Roivant Sciences jumped 13.2% today. With many investors piling into ROIV without a second thought, it may be a good idea to take a closer look at the stock. Here are some quick facts to get you started:

Roivant Sciences has moved -4.8% over the last year, and the S&P 500 logged a change of -18.6%
ROIV has an average analyst rating of buy and is -28.45% away from its mean target price of $12.88 per share
Its trailing earnings per share (Eps) is $-4.52
Roivant Sciences has a trailing 12 month Price to Earnings (P/E) ratio of -2.0 while the S&P 500 average is 15.97
Its forward earnings per share (Eps) is $-1.33 and its forward P/E ratio is -6.9
The company has a Price to Book (P/B) ratio of 5.6 in contrast to the S&P 500's average ratio of 2.95
Roivant Sciences is part of the Healthcare sector, which has an average P/E ratio of 13.21 and an average P/B of 4.07
The company has a free cash flow of $-710,943,232.00, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.